Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.
about
Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteersCardiotoxicity of fluoroquinolonesAntimicrobial safety: focus on fluoroquinolonesAnalysis of West Virginia medicaid claims data for the prevalence of medical conditions and use of drugs likely to cause QT prolongation in patients with schizophrenia.Gatifloxacin-induced QTc prolongation and ventricular tachycardia.Efavirenz-associated QT prolongation and Torsade de Pointes arrhythmia.Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings.Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical SignificanceMacrolide antibiotics and the risk of cardiac arrhythmiasCardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.Prulifloxacin: a new antibacterial fluoroquinolone.Torsades de pointes associated with fluoroquinolones.Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System.Biological warfare -- a growing healthcare concern.Evaluation and cost assessment of fluoroquinolones in community-acquired respiratory infections.Acquired long QT syndrome: risk assessment, prudent prescribing and monitoring, and patient education.Levofloxacin: update and perspectives on one of the original 'respiratory quinolones'.Update on the cardiac safety of moxifloxacin.Effect of combined fluoroquinolone and azole use on QT prolongation in hematology patients.Incidence of Sustained Ventricular Tachycardia in Patients with Prolonged QTc After the Administration of Azithromycin: A Retrospective Study.Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias.Severe QT interval prolongation associated with moxifloxacin: a case reportSkin and skin structure infections: treatment with newer generation fluoroquinolones.QT prolongation in the intensive care unit: commonly used medications and the impact of drug-drug interactions.Weighing the adverse cardiac effects of fluoroquinolones: A risk perspective.Gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis: safety, efficacy and patient perspective.Macrolide and fluoroquinolone mediated cardiac arrhythmias: clinical considerations and comprehensive review.QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.Effects of three fluoroquinolones on QT analysis after standard treatment courses.Moxifloxacin does increase the corrected QT interval.Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors.Evacetrapib at a supratherapeutic steady state concentration does not prolong QT in a thorough QT/QTc study in healthy participants.Use of QT-prolonging medications in US emergency departments, 1995-2009.Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy.
P2860
Q24607103-D04B02C9-26D8-482F-9BE8-5CBCE37107D9Q28209298-96F4BADB-3037-44F3-9DD8-4BA56A1D5D79Q28255152-08E1E73B-3F1B-4A7C-B893-4E445E9A772FQ30832167-9C0EFD61-43FD-4B67-B223-0C66A36D1B34Q33146245-D8F71EB8-5ABF-46DC-AC2F-D2877DEB8980Q33147714-1DF7DA75-06AD-45BE-8B9A-D38C46CD29B0Q33151312-A6316271-ECA0-46B8-9F9F-2EC8FF9661EFQ33653994-C5806C3D-DC76-421D-8646-EADB774EF084Q33772270-C2ED34DA-C841-40E2-8121-CF1FCBFB8403Q34536016-58845C24-B453-4D15-BB0A-110D11059B43Q34564526-1E503E9A-D88F-4918-9B5A-253FB12D6BA8Q34639737-D7DFC213-AF97-418E-A261-E51CD6130E20Q34711627-320C90DD-7680-4D4B-924A-8B87BBEB2BC5Q34747918-36E5EC1B-B424-4539-A81F-810E466E3B25Q34789110-8B1FA308-2C81-40B4-8F76-4ACA9D1995B1Q34957359-CCAD16D8-1B69-4DEB-ADA5-1EA79603188FQ35917230-237BF01B-EFBC-40BD-9039-B4F12BB97B94Q36345861-52B27AE5-CFCE-4EA4-88F7-699A6F95717CQ36667015-BF8A099B-FF4C-460D-9E3D-AFC9699B78BBQ36761496-369152AA-6A2D-4B74-9E29-DDEC55F3F5F7Q36886266-35B52E71-D43A-4E07-97F5-4FBA3DB3DAC3Q37052214-D1AF2C8A-52B8-4D05-AC0C-37DE3A91EE44Q37116838-E6B3E7C6-DDD8-435B-A0C7-5A6016743475Q37727223-475BBE6B-70FF-4E2B-AAD0-823069EC9AE6Q38502981-0703557B-7509-4D5E-8AC1-32EE5F25F270Q39675169-3AD93658-D26B-4442-B482-A2FF69BE9AEFQ40108685-C2AB869C-8976-434A-860E-154717537BE4Q40515779-60E6BC7F-ED48-41D7-97E1-20D68DAB0449Q42680174-AA61FCE4-2ACA-4594-91F6-57A92D668E98Q43743491-A15A62B9-E6EB-4CC6-B4BD-6DEEDCBFC7BCQ43838827-6FCE0F8F-817D-4CE6-8C61-4352716D4B38Q43878559-C22D5BB6-2B2D-4D46-9D2F-AAF90B690120Q45180372-63517B47-A65B-44E3-ABDA-50F497B4C1E2Q46041143-118C4261-0CBA-4D60-A062-7A6C2A76C501Q47664190-9B53CCCD-31F1-4B01-B117-A5884B1F216C
P2860
Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Risk assessment for antimicrob ...... ation and torsades de pointes.
@ast
Risk assessment for antimicrob ...... ation and torsades de pointes.
@en
Risk assessment for antimicrob ...... ation and torsades de pointes.
@nl
type
label
Risk assessment for antimicrob ...... ation and torsades de pointes.
@ast
Risk assessment for antimicrob ...... ation and torsades de pointes.
@en
Risk assessment for antimicrob ...... ation and torsades de pointes.
@nl
prefLabel
Risk assessment for antimicrob ...... ation and torsades de pointes.
@ast
Risk assessment for antimicrob ...... ation and torsades de pointes.
@en
Risk assessment for antimicrob ...... ation and torsades de pointes.
@nl
P2860
P1433
P1476
Risk assessment for antimicrob ...... ation and torsades de pointes.
@en
P2093
Owens RC Jr
P2860
P304
P356
10.1592/PHCO.21.3.301.34206
P407
P577
2001-03-01T00:00:00Z